Vitti Labs announced that the US FDA has approved its Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination of umbilical cord mesenchymal stem cell and umbilical cord mesenchymal stem cell exosomes for the treatment of Acute Respiratory Distress Syndrome associated with COVID-19.
[Vitti Labs (PR Newswire, Inc.)]
7992332
{7992332:nan}
apa
50
1
168468
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
